Big Pharma conspiracy deepens; FDA considers ‘drug therapy’ for teen vapers
In a public hearing on Friday, Commissioner Scott Gottlieb of the U.S. Food and Drug Administration (FDA) claimed that the agency is discussing drug therapies for young adults addicted to vaping. He also threatened to implement a nationwide ban on all sales of vaping devices and e-liquids -even for adult smokers trying to quit. If teen e-cig usage rates do not begin to decline sharply and immediately within the first few months of 2019, he warns that the vaping industry may face an “existential threat,” presumably against its very existence.
These two rather startling statements have one thing in common. They both will directly benefit Big Pharma. Given Dr. Gottlieb’s somewhat sorted history with pharmaceutical companies, his statements last Friday are being seen as red flags among many within the vaping community.
Big Pharma has always had the most to lose financially as the popularity of vaping has steadily increased in recent years. Since many people are turning to vaping as a safe and effective alternative to combustible tobacco products, profits from the sales of more conventional stop smoking aids like the patch and nicotine gums continue to dwindle.
One of the manufacturers of these products is GlaxoSmithKline, a Big Pharma company of which Dr. Gottlieb previously served as a member of its Board of Directors. In fact, Scott Gottlieb has served on the boards of no less than five pharmaceutical companies while simultaneously funding numerous medical startups. His past history with drug companies was even a cause of brief concern during his Senate confirmation hears in early 2017.
(Image courtesy of Shutterstock)